The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.

Slides:



Advertisements
Similar presentations
Engaging Patients and Other Stakeholders in Clinical Research
Advertisements

County’s Healthcare Plan Red Flags Then and Now Jan 6, 1999 Item F3 beds for criminals – Storms, Hart, Easterling, Norman…voted unanimously to drain funds.
Community Medic Initiative. Community Medic Fulfilling our mission statement: DGEMS provides for the health and well-being of our communities with a team.
Dr. John E. Niederhuber Director, National Cancer Institute Board of Scientific Advisors June 22, 2009 NCI Director’s Update.
PDUFA Reauthorization: Advancing Rare Disease and Orphan Drug Policies Steven Grossman, President, HPS Group, LLC To National Organization of Rare Disorders.
IHS Budget Formulation Indian Health Service 2013 Virtual Tribal Consultation Summit November 5, 2013.
Cavarocchi  Ruscio  Dennis Associates Advocacy: Understanding the Process (or How do I gain a fair advantage?) 1.
CPT Review of Drug Administration Services AMA Presentation.
Chubaka Producciones Presenta :.
Environmental Justice (EJ) & Community-Based Transportation Planning (CBTP) Grant Programs California Department of Transportation District 3 January 25,
2012 JANUARY Sun Mon Tue Wed Thu Fri Sat
Graduate Medical Education Reimbursement and Residency Funding Prepared by: Erin E. Schneider, MD Emergency Medicine Resident, PGY-2 Oregon Health and.
Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy
Haffner Associates, LLC1 Orphan Drugs – 2011 What’s Happening? Women in BIO Marlene E. Haffner, MD, MPH Office 301.
Health Care Policy: What You Should Know American Nephrology Nurses Association (ANNA) Long Island Chapter, Fall Conference November 13, 2013 Carle Place,
COMPARATIVE EFFECTIVENESS RESEARCH Public Policy Interest and Issues Jeanne Lambrew, PhD Associate Professor LBJ School of Public Affairs National Health.
Communities of Care NASCSP Conference Marisue Garganta Director, Community Health Integration Dignity Health, St. Joseph’s Hospital and Medical Center.
Karmen Hanson, MA Senior Policy Specialist National Conference of State Legislatures 340B Drug Purchasing: Options for States Overview of State Rx & 340B.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
North Dakota Medicaid Expansion Julie Schwab, MNA, MMGT Director of Medical Services North Dakota Department of Human Services.
Evidence-Based Medicine: Making Today’s Goals Tomorrow’s Reality Carolyn M. Clancy, MD Director Agency for Healthcare Research and Quality Washington,
Amy Comstock Rick, JD Creative Advocacy Not Limited by Staff or Budget NINDS Partners Session September 11, 2013.
Washington D.C., USA, July 2012www.aids2012.org Addressing the NSEP Shortfall in the USA: Local Problems, Local Solutions Paola Barahona, MPH Project.
2013 State Office of Rural Health Orientation September 11, 2013 Laura B. Hudson, MPA Manager, Program Services & Contracting /
Annual Federal Budget Briefing The President’s FY 2010 Budget Proposal: Implications for Housing and Homeless Assistance Tuesday, May 12 2:00 – 3:00 pm.
“An Act Relative to the Achievement Gap” Report of the Superintendent Melinda J. Boone, Ed.D. March 4, 2010.
FY15 Rural Opioid Overdose Reversal Grant Program HRSA PRE-REVIEW CONFERENCE CALL.
2015 Rural Health Summit National Organization of State Offices of Rural Health Rural Recruitment and Retention Network National Cooperative of Health.
Crossroads Teen Driving is a program of Children’s Hospital of Wisconsin We partner with the Wisconsin Department of Transportation and State Farm This.
Quality of Care A Group VI. Public Policy Problem The lack of ability to generate population-based data/information from individual practices or health.
Implementing a Rapid HIV Testing Guideline for L&D NNEPQIN April 30, 2007.
Robert H. Roswell, M.D. Oklahoma Hospital Association September 1, 2009.
Legislative/Executive Branch Update Thomas M. Leary Director, Federal Affairs September 23, 2005.
Recommendations and a Plan for Preventing Preterm Birth Secretary’s Advisory Committee on Infant Mortality (SACIM) August 10, 2015.
Legislative Policy Committee ISAC Board approved concept at their meeting in December.
Specialty Practice Pathologist Patient cap.org v. # Advocacy Workshop for Engaged Pathologists Mike Giuliani, Senior Director, Legislation and Political.
What’s Happening with School-Based Health Centers? Brenda Barron, Director of Field Operations Director of Field Operations School Health Initiatives Midwestern.
ACUTE-CRISIS PSYCHIATRIC SERVICES DEVELOPMENT INITIATIVE DC Hospital Association Department of Mental Health June 30, 2004.
Medicaid In The Schools (MITS) National Picture of School-Based Medicaid Programs January 2008.
STAKEHOLDER CALL/MEETING TO DISCUSS AND PROVIDE INPUT ON ZEV INCENTIVE PROGRAM GUIDELINES CALIFORNIA AIR RESOURCES BOARD March 7,
Government and Voluntary Agencies. WHO World Health Organization International agency sponsored by United Nations compiles statistics/information on disease.
National Policy Update October 15, 2015 Chuck Ingoglia, MSW.
Introduction to US Health Care Unit 4 Chapter 14 Public Health Policy 14-1.
Introduction to the NIH
Government, Non- profit agencies, & Insurance Plans.
PDUFA Needs to be More Orphan-Friendly Diane Edquist Dorman Vice President, Public Policy National Organization for Rare Disorder (NORD)
FDA Office of Orphan Products Development
HIPAA History March 3, HIPAA Ruling Health Insurance Portability Accountability Act Health Insurance Portability Accountability Act Passed by Congress.
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
2011 Calendar Important Dates/Events/Homework. SunSatFriThursWedTuesMon January
What HIT Policy Changes Will Mean for MedTech October 22, 2004 Blair Childs Executive Vice President, Strategic Planning & Implementation.
2015 Advocacy Forecast Rebecca Kelly Vice President, Advocacy.
1 Maximizing the Impact of Comparative Effectiveness Research: The Role of the DEcIDE Consortia Scott R. Smith, PhD AHRQ Center for Outcomes & Evidence.
July 2007 SundayMondayTuesdayWednesdayThursdayFridaySaturday
Health Departments and HIV Screening Institute of Medicine Workshop 1: Screening and Access to Care April 15, 2010 Natalie Cramer, Associate Director,
Sources: National Journal Research 2016, Jordain Carney, “Senate passes opioid abuse bill,” The Hill, March 10, 2016; Nadia Kounang, “Obama Announces New.
Unit C: Health Care Systems Part 3 Health Team Relations.
Government, Non-profit agencies, & Insurance Plans
Budget and Appropriations 101
American Clinical Laboratory Association
Gazing Into the Crystal Ball Budget and Legislative Update March 23,
Government, Non-profit agencies, & Insurance Plans
Suzanne M. Sensabaugh, MS, MBA
New Midwifery Practice Orientation Presentation to the Association of Ontario Midwives June 20, 2014.
McDonald’s calendar 2007.
Pediatric Therapeutics Still working to get it right for kids
McDonald’s calendar 2007.
2015 January February March April May June July August September
Advocacy 101 Kristen Angell, Associate Director of Advocacy
Presentation transcript:

The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International Conference on Rare Diseases and Orphan Drugs Stockholm February 14-16, 2005

 Dedicated to the identification, treatment and cure of rare disorders  Education, advocacy, research and service

 NORD funded its first research grants totaling $142,000  Today - nearly $4 million has been awarded to fund 97 grants and fellowships  Fall 2005 – 13 additional grants totaling $430,000 will be awarded $4.5 Million in Research Grants…

 Small grants to academic scientists to study new treatments or diagnostics for rare diseases  May provide preliminary data indicating that a treatment may be safe and effective when used for a larger number of patients

 Use the preliminary data to apply for larger multi-year government grants, or;  Attract a commercial sponsor who will manufacture an orphan product and get FDA approval

Restricted Grants Criteria If the total donated for a specific disease is less than $1,000 after 2 years Funds are transferred to general research If the total donated for a specific disease is more than $1,000 but less than $5,000 after 4 years Funds transferred to research on related diseases

If the total donated for a specific disease is more than $5,000 but less than $10,000 after 6 years Funds transferred to research on related diseases If the total donated for a specific disease is more than $10,000 but less than $15,000 after 8 years Funds transferred to research on related diseases

If the total donated for research for a specific diseases is less than $25,000 in 10 years Funds are transferred to research on related diseases

The Power of the Many… The Rare Disease Community in the United States

Nearly 30 Million Americans Living With One of the 6,000 Known Rare Diseases…

August 3, Introduction of the Rare Diseases Act March 28, 2002 – Introduction of the Rare Diseases Act March 28, 2002 – Introduction of the Rare Diseases Orphan Product Development Act

November 6, President Bush signs both the the Rare Diseases Act and the Rare Diseases Orphan Product Development Act

May 19, 2003 – Resolution passed in the House of Representatives commemorating the 20 th Anniversary of the Orphan Drug Act and NORD

July 20, 2003 – Introduction of the Medicare Patient Access to Drugs for Rare Diseases Act of 2003

November 3, 2003 – NIH announces Rare Diseases Clinical Research Network $51 million in grant funding over 5 years 7 Rare Diseases Clinical Research Centers Data and Technology Coordinating Center Trans-NIH Working Group on Rare Diseases Research

December 8, 2003 – Medicare Prescription Drug Improvement and Modernization Act (MMA) signed into law Ensured adequate reimbursement for orphan products administered in a hospital or outpatient setting for 2004 and 2005

June, 2004 – FY 2005 FDA Appropriations Language $1.2 million increase for the Orphan Products Research Grants Program Encourages FDA to speed development and approval of orphan drugs

June, 2004 – FY 2005 NIH Appropriations Language Commends Office of Rare Diseases for rapid progress Encourages increased research/ interventions Encourages NIH to pursue exploratory grants and proof of concept studies

Concerned that Medicare patients with rare diseases may have difficulties accessing care that involves orphan drugs Encourages CMS to carefully consider the impact on this population in proposing regulations Encourages CMS to solicit the views of the OOPD, ORD, and stakeholders before determining whether an access problem exists or would be made worse by proposed regulations

October 27, 2004 – Fabry Disease Network Stakeholders Meeting, Toronto, Canada Fabry Network of Excellence Replegal® and Fabrazyme® approved by Health Canada Common Drug Review would not recommend reimbursement January 2005 approved for reimbursement

Federal Funding Increases Office of Rare Diseases, NIH $2.1 million $51 million for research $16 million Orphan Products Research Grants Program, FDA 2005 – $1.2 million increase

Summary

The Power of Millions… Increased awareness of rare diseases throughout the U.S. Congress and government agencies Increased research funding Empowered to affect legislation and regulations Empowered to change their lives

Without the Rare Disease Community There Would Be NO… Orphan Drug Act Office of Orphan Product Development, FDA Orphan Products Research Grants Office of Rare Diseases, NIH ICORD

Thank you…

Contact Information… Diane E. Dorman Vice President for Public Policy NORD – Washington Office th Street, NW Washington, DC (202)

Contact Information… Abbey S. Meyers President National Organization for Rare Disorders (NORD) 55 Kenosia Avenue Danbury, CT (203)